First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status is a paper indexed in ScholarIQ from OpenAlex.

How many citations does First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status have?

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status has 147 citations in the OpenAlex counts ScholarIQ stores.

When was First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status published?

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status has 2020 year in the ScholarIQ index.

What is the open-access status of First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status?

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status has green oa status in the ScholarIQ index.

What is the DOI of First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status?

The DOI for First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status is on the source record.

What is the PMID of First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status?

The PMID for First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status is on the source record.

What is the OpenAlex record for First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status?

The OpenAlex for First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status is on the source record.